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Abstract BACKGROUND: Breast cancer is the most common malignancy in women in the 
U.S. and Europe. In the early stages of the disease, women are treated surgically, 
which is supplemented with hormonal therapy, immuno-, chemo- or radiother-
apy. Postoperative qualification for further treatment is based on clinical stage, 
the pathology of the tumor and classic prognostic factors. Despite that, among 
patients with breast cancer in early stages of clinical advancement, there is a rela-
tively large proportion of observed tumor recurrence. These observations oblige 
the search for additional prognostic factors that determine the progression of the 
disease faster, according to which, could emerge a group of women at increased 
risk of recurrence of the disease. 
AIM: The aim of this paper is to determine the meaning of the expression of 
selected metalloproteinases as prognostic factors in breast cancer. 
METHODS: The study group consisted of 108 patients ages 26 to 86 years treated 
surgically from 1994 to 2000 because of primary breast cancer in the early clinical 
stage, ie stage I and II according to TNM classification. 
RESULTS: Between two of the tested metalloproteinases (MMP-2 and MMP-11) 
only MMP-2 appears to have prognostic significance in early forms of breast 
cancer, and its strong expression is associated with shorter survival. 
INTRODUCTION
Breast cancer is the most common malignancy in 
women in the United States and Europe, including 
Poland. This represents approximately 23% of all 
cases of cancer in women (Jemal et al. 2009) and 
the risk of cancer of this organ in our country is 
growing.
According to the American Cancer Society 
(ACS) in the United States, a country with the 
highest number of cases, it is estimated that in 
2011 there are 207,000 new cases of cancer, and 
one in eight women born today will develop breast 
cancer.
The most important risk factor for breast cancer 
in women is age. Average age of breast cancer diag-
nosis is 61 years. Cancer occurs more frequently 
among women of higher socioeconomic classes, 
residents of developed countries, more often in 
women living in the city than in rural areas, and 
often in unmarried women (Jassem 1998; Kreien-
berg et al. 2002)
Exposure to endogenous and exogenous estro-
gen is one of known risk factors for breast cancer. It 
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is frequently observed in women who experience early 
menarche, late menopause, women who for a long time 
been using hormone replacement therapy, in women 
with obesity, nulliparous, or those in whom the first 
pregnancy occurred after 30 years life (Collaborative 
Group on Hormonal Factors in Breast Cancer 2002). 
As a risk factor also mentioned is hyperinsulinemia and 
a diet rich in animal fats and alcohol. Approximately 
10% of all cases of breast cancer are in patients with a 
positive family history, some of them are related geneti-
cally and usually with a mutation within the BRCA1 
and BRCA2 genes (Cortesi et al. 2010). The factors that 
reduce the risk of developing breast cancer include late 
occurrence of menarche, unilateral or bilateral oopho-
rectomy, pregnancy before age twenty, and breastfeed-
ing. Also stressed is the importance of regular exercise, 
proper body mass index and diet low in fat, which is 
associated with prevention of hyperinsulinemia.
In the detection of cancerous changes in the breasts, 
in addition to the patient’s history and examination by 
palpation is mammography, ultrasound, and in some 
cases the magnetic resonance imaging. 
Diagnosis shell be confirmed by examination of 
cytological material obtained by fine-needle biopsy 
(rarely) or more histological examination of tissue 
samples obtained by core biopsy and needle biopsy, ste-
reotactic biopsy or open surgery.
Currently in early stages of breast cancer the basic 
treatment is modified radical mastectomy or the breast 
conserving therapy (tumorectomy or quadrantectomy) 
combined with radiation. During the surgical proce-
dure one also removes the axillary lymph nodes on the 
side of the breast tumor. Surgical treatment is usually 
supplemented depending on the type of surgery, tumor 
characteristics and general condition of patient by 
radiation therapy, hormone therapy, chemotherapy or 
immunotherapy. This depends mainly on the presence 
of cancer metastasis to lymph nodes and the presence 
of steroid receptors.
It is estimated that in clinical stage I of breast cancer 
5-year survival is around 90%, in II A-80%, II B-70%, in 
III-40%, and in IV stage-10% (Jassem 1998). However, 
the relapse occurs even after 10 or 20 years after diagno-
sis and primary treatment of the disease.
It is known that breast cancer is a systemic disease 
from the beginning, and the results of treatment and 
patient survival is dependent on distant metastases. It 
is therefore important to assess the risk of their occur-
rence and coordinate individualized treatment. With 
this in mind, one routinely takes into account such fac-
tors as patient age as well as size, type and degree of 
histological tumor differentiation, lymph node status, 
the presence of steroid receptors, HER2 protein expres-
sion and the presence of cancer cells in the vessels sur-
rounding the tumor (Untch et al. 2004; Goldhirsch et 
al. 2009).
With the introduction of mammography screen-
ing, an increasing trend toward early detection of 
breast cancers has been observed. In these patients, it 
is important to select treatment that will provide maxi-
mum benefit with the least side effects. It is interesting 
that among patients with operable breast cancer at less 
advanced stages of disease development a fairly large 
proportion of observed tumor recurrence is observed. 
These observations oblige us to seek additional factors 
that determine the faster progression of disease and its 
recurrence.
Failures in the treatment of solid tumors depend on 
tumor cell metastases, especially distant. Traditionally, 
it is believed that breast cancer metastases are initially 
formed through the lymph nodes and in the later stages, 
hematogenously. 
However, more recent reports indicate that cancer 
cells are present in the bloodstream from the beginning 
of the disease, and therefore should be treated as gener-
alized regardless of its duration (Untch et al. 2004).
In breast cancer the most common metastases to 
regional lymph nodes are created by the invasion of 
cancer cells to mammary gland lymphatic vessels. 
These vessels form a plexus located in the pectora-
lis major fascia from there they direct to the axillary 
lymph nodes (Jassem 1998). Breast cancer also spreads 
through the blood and in this way, cancer cells metas-
tasize to bone, lung, liver and brain, but also described 
is the occurrence of tumor metastasis to the ovaries, to 
the other breast, adrenal gland, skin and subcutaneous 
tissue (Kreienberg et al. 2002). Regardless of the loca-
tion of their metastases, formation takes place through 
the same road and consists of several phases.
Cancer cells must initially overcome the intercel-
lular adhesion and detach from the primary tumor 
mass, move through the blood vessel endothelium or 
lymphatic system, and then after reaching the target 
location must overcome a natural barrier tissue such 
as the basement membrane and invade the extracel-
lular matrix (ECM). This process is possible by the 
enzymatic digestion of proteins forming the barrier. At 
this stage, the key role is played by proteolytic enzymes, 
including metalloproteinases (Garbett et al. 2000). By 
digestion of basement membranes, and tissue matrix 
(ECM), metalloproteinases allow angiogenesis, local 
expansion (Sharma et al. 2004), and distant metastasis 
of cancer (Polette & Brimbaut 1998).
Metalloproteinases are more than twenty enzymes 
(Table 1) (Nelson et al. 2000) of the type of extracel-
lular endopeptidase, with some common amino acid 
sequences, containing a zinc ion (De Clerck 2000; Ege-
blad & Werb 2002; Jezierska & Motyl 2009; Matrisian 
et al. 1990; McCawley & Matrisian 2000; McCawley & 
Matrisian 1998; Minn et al. 2005; Nagase et al. 1992; 
Polette et al. 2004; Rudoplh-Owen et al. 1998). The 
zinc ion is part of the catalytic center of these enzymes, 
hence of crucial importance for their function (Fig-
ures 1 and 2).
These enzymes play a role in physiological processes 
such as embryogenesis, angiogenesis, wound healing, 
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bone growth, menstruation, childbirth and postpartum 
uterine involution, development and disappearance of 
Graafian follicles, involution of the breasts after lacta-
tion (Benaud et al. 1998; Tlsty 2001) and pathological 
conditions, such as growth and formation of tumor 
metastases (Bister et al. 2004; Cai et al. 2007; Decock 
2007; Decock 2005; Gaibyan et al. 2004; Jäälinojä et 
al. 2000; Koblinski et al. 2000; McCarthy et al. 1999; 
Nielsen et al. 2001; Settner et al. 2009; Väisänen et al. 
2000) the formation of cirrhosis, hypertensive vascular 
remodeling and atherosclerotic plaque formation and 
changes associated with chronic inflammation- for 
example, in rheumatoid arthritis and periodontitis.
These enzymes can be divided into several groups 
depending on their function (Jones et al. 1999; Pasco et 
al. 2003; Pei & Weiss 1995; Remacle et al. 1998; Reed et 
al. 2000; Sato et al. 1997). And so they are: collagenases 
(MMP-1, MMP-8), gelatinases (MMP-2, MMP-9), 
membrane-type metalloproteinases (MMP-14-17) and 
stromelysins (MMP-11, MMP-13). A large part of this 
group of enzymes is involved directly in the process of 
tumor expansion through proteolytic activity.
Metalloproteinase 2 (MMP-2) belongs to the gela-
tinases, is released from the cell into the extracellu-
lar space as a proenzyme and activated by cutting off 
the N-terminal propeptide (Morgunova et al. 1999). 
It was shown that the role of the activator MMP-2 is 
likely to be one of transmembrane metalloproteinase 
(MT1-MMP) (Ishigaki et al. 1999; Jones et al. 1999; 
Morgunova et al. 1999; Polette & Brimbaut 1998) and 
in the process of activation of MMP-2 it becomes part 
of a complex molecule inhibitor of metalloproteinase-2 
(TIMP2) (Lafleur et al. 2003; Nakapoulou et al. 2002), 
which when combined with proMMP-2, allows its acti-
vation. Gelatinase A exhibits proteolytic activity mainly 
in relation to type IV collagen and constituent of basal 
membranes (Cai et al. 2007). It has been proven, how-
ever, that the substrates of this enzyme are also other 
types of collagen (I, V, VII, X, XI, XIV) and elastin, 
fibronectin, aggrecan, osteonectin, laminin, proteo-
glycans and other metalloproteinases such as MMP-1, 
MMP-9 and MMP-13.
Its function, which involves the basal membrane pro-
tein digestion with subsequent interruption of continu-
ity, is typical for the whole group of zinc ion dependent 
proteases. This mechanism is one of the cornerstones 
of the process of expansion and metastasis of cancer. 
Additionally, demonstrating the enzymatic activity in 
relation to other metalloproteinases, it activates some 
of them, thus exacerbating the process.
Increased expression of MMP-2 are found in many 
types of cancers such as breast cancer, bronchus, colon, 
stomach, bladder, prostate and ovarian cancers (Chan-
dru et al. 2007; Ornstein & Cohn 2002; Perigny et al. 
2008; Talvensari-Mattila et al. 2005; Trudel et al. 2003; 
Väisänen et al. 2000). The literature has emphasized 
its relationship with the tendency to produce distant 
metastases, a shorter survival and poorer prognosis, 
especially in breast cancer with metastases to lymph 
nodes.
Metalloproteinase 11 (MMP-11) is a metallopro-
teinase first identified in breast cancer. It is produced 
mainly by fibroblast tissue matrix (Basset et al. 1997; 
Louis et al. 2005; Masson et al. 1998; Wang & Tetu 2002; 
Wiseman & Werb 2002; Wolf et al. 1993). Its role is 
not fully explained, because unlike the other enzymes 
of this group, it shows no strong proteolytic activity 
against components of the basal membrane. Proteolytic 
activity was demonstrated, however on protein growth 
factors and cytokines of intercellular space (Bigg et al. 
1997). It has been proven that its substrates include, α-1 
proteinase inhibitor and α-2 anti-plasmin. Since the 
proteinase inhibitor α-1 is the main inhibitor of elas-
tase, thus indirectly by its proteolysis, enhances elas-
tase-dependent process of tissue damage. However the 
distribution of α-2 antiplasmin increases the amount 
of free plasmin, which may increase the activation of 
other metalloproteinases (Louis et al. 2005).
It is suspected that this enzyme plays a role in con-
trol reactions between tumor cells and the environment 
(ECM). Its effect is more concerned with survival of 
cancer cells in the tissues of the host, and the process 
of tumor growth initialization rather than the process 
of metastasis (Carter et al. 1989; Noël et al. 1995; Rio 
& Foidart 2000). It is interesting that elevated expres-
sion of this enzyme was found in dysplastic foci such as 
those found in the airways, which show precancerous 
changes in contrast to areas of meta-and hyperplasia 
(Lafleur et al. 2003). MMP-11 expression was observed 
both in fibroblasts adjacent to the tumor (Selvey et al. 
2004) and in the cytoplasm of epithelial cancer cells, but 
there are reports of greater prognostic importance of 
the presence of this enzyme in cancer cells (Engel 1997).
The importance of metalloproteinases in the course 
of cancer is the subject of research since about 15 years. 
It is suggested that the increased expression of MMP-11 
and MMP-2 is an unfavorable prognostic factor in 
breast cancer (Abrial et al. 2005; Bria et al. 2010), and 
the relationship between the increased expression and 
lymph node involvement was proven in studies of other 
cancers (non-small cell bronchial carcinoma, colorec-
tal, head and neck and skin) (Baker at al. 2002; Bister 
et al. 2004; Skoglund et al. 2004). Nakopoulou studies 
highlighted the association of increased expression of 
these enzymes with a worse survival rate and axillary 
lymph node involvement in breast cancer (Benaud et 
al. 1998). The increasing ability to detect breast cancer 
in its early stages of clinical advancement oblige us to 
explore additional prognostic factors, which will allow 
individualize further systemic therapy. It may help to 
reduce the recurrence of cancer. Also of interest would 
be to determine the level of expression of the described 
metalloproteinases in patients with early forms of 
breast cancer without axillary lymph node involvement 
or the presence of single tumor cell metastasis to lymph 
nodes in terms of outcomes.
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OBJECTIVES OF WORK
The aim of this paper is to determine the meaning of 
the expression of selected metalloproteinases as prog-
nostic factors in breast cancer. To achieve this goal, the 
following will be defined:
1. The level of expression of metalloproteinases 2 and 
metalloproteinase 11 in breast cancer changes
2. The relationship between outcomes and the degree 
of expression of studied metalloproteinases-MMP-2 
and MMP-11
MATERIAL AND METHODS
The study group consisted of 108 patients ages 26 to 86 
years treated surgically at the Department of Gynecol-
ogy and Oncology CMUJ from 1994 to 2000 because 
of primary breast cancer in the early clinical stage, ie 
stage I and II according to TNM classification and who 
remained in outpatient care at the Oncology Clinic of 
Gynecology and Oncology Clinic CMUJ.
The average age of patients studied was 55.2 years. 
Most of them, as many as 45 (42%) women were 55 years 
or more at the time of diagnosis. Groups between 46 
and 55 years of age was 38 (35.0%) women, 22 (20.3%) 
patients were aged 36 to 45 years, while 3 (2.7%) had 
less than 35 years at the time of diagnosis 
Analysis of family history revealed that in 73 (67.6%) 
cases, no first degree and second degree relatives were 
ill with breast cancer and / or ovarian cancer. Data from 
the obstetric history showed that 12 (11.1%) women 
had never been pregnant, 12 (11.1%) women had been 
pregnant once, 30 (27.8%) women were pregnant twice, 
and 54 (50.0%), three or more times. 15 (13.5%) women 
were not pregnant, 21 (19.4%) gave birth once, 40 
(37.0%) gave birth twice, and 32 (30.1%) women gave 
birth three or more times; because 60 (55.6%) women 
breast-fed for longer than six months, 17 (15.7%) 
women breast-fed, but less than six months, and 31 
(28.7%) women did not breast-feed.
Menstruation history indicate that 18 (16.8%) 
women got their first menstruation before the age of 10, 
48 (44.4%) women got their first menstruation between 
the ages of 11–12, 36 (33.3%) between 13–14 years of 
age and 6 (5.5%) women got their first menstruation 
after 14 years of age.
In the study group, 65 (60.2%) women were postmeno-
pausal. Within this group, the last menstruation being 
between 45–47 years of age included 9 (13.8%) of the 
women, between the ages of 48–50 included 33 (50.7%) 
women, between the ages of 51–52 included 17 (26.2%) 
women and above 53 years of age, 6 (9.2%) women.
Only 9 (8.3%) women used a hormone replacement 
therapy for 5 years or longer, 6 (5.5%) used it less than 
5 years, and the remaining 93 (86.2%) women were not 
taking hormone replacement therapy.
The first stage of treatment was surgery. In 101 
(93.5%) cases, modified radical mastectomy was per-
formed involving the total excision with skin and lymph 
nodes on the operated side, sparing the pectoral muscles. 
In 7 (6.5%) cases, breast conserving surgery was per-
formed, with removal of part of axillary lymph nodes on 
the side of the operated breast followed by radiotherapy.
Chemotherapy was given to 40 (37%) patients. It was 
used primarily in patients with metastasis to axillary 
lymph nodes, or in the presence of adverse prognostic 
factors such as low histological grade of tumor dif-
ferentiation, the young age of the patient, overexpres-
sion of the HER2 protein, as well as in the absence of 
expression of steroid receptors. In 36 (33.3%) cases, the 
chemotherapy regimen was based on 5 – fluorouracil, 
cyclophosphamide and methotrexate (CMF), while in 
4 (3.7%) cases, patients received anthracyclines (AC).
In 49 (45%) patients in whom expression of steroid 
receptors was confirmed hormone therapy was pre-
scribed, of which 41 (38%) cases used Tamoxifen, in 5 
(4.2%) cases Anastrozole, and in 3 (2,8%) cases Anas-
trozole, and Tamoxifen.
Aromatase inhibitors were used in postmenopausal 
patients with coexistence of risk factors for thrombo-
embolism or those who poorly tolerate Tamoxifen 
which would rule out its use.
After the surgery the patient remained in control 
of the outpatient Oncology Clinic of Gynecology and 
Oncology Department CMUJ. Over the first five years, 
visits took place every 3–6 months, and by next year, 
every 6–12 months.
This work has gained a positive opinion of the Com-
mission of Bioethics at the Jagiellonian University No. 
KBET/16/B/2006.
Immunohistochemical recognition of tested 
metalloproteinases
The level of expression of MMP-2 and MMP-11 was 
determined by immunohistochemistry in tumor biop-
sies fixed in 15% formalin solution. For this purpose, 
3 micrometer sections were prepared which, after 
immersion in 20% rabbit serum (DAKO A / S) were 
subjected to incubation with mouse monoclonal anti-
bodies against MMP-2 and MMP-11 (Lab Vision). The 
resulting material was subjected to incubation at room 
temperature for about 12 hours. In a further step rabbit, 
biotinylated secondary antibodies against mouse anti-
bodies (DAKO A / S) suspended in 3% human plasma 
at 1:400 ratio were added. Samples were incubated 
at room temperature for 30 min. with peroxidase-
complexes of Biotin-Streptavidin. Visualization was 
performed using diaminobenzidine, and nuclei were 
stained with hematoxylin.
These reactions are made in line with the correct 
application of immunohistochemical methods, con-
ducting the positive controls.
Statistical methods
The collected research material was presented in narra-
tive form based on the number and frequency of tested 
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characteristics. Quantitative variables are presented by 
analyzing the distribution parameters of the arithmetic 
mean and standard deviation.
The analysis was performed for the treatment 
outcomes as end points of death. Survival time was 
counted from the date of surgery. The results of treat-
ment are presented using the Kaplan-Meier survival at 
10 years of observation. For the complete observation 
are those who have failed treatment or completed a 
10-year observation.
The effect of the level of expression of metallopro-
teinases in the course of these curves was analyzed 
using the logrank test.
Statistical significance for these tests was adopted for 
which the level of significance was less than or equal to 
0.05 (p≤0.05).
Calculations were performed using the statistical 
package STATISTICA 8 PL licensed for the Jagiellonian 
University.
RESULTS
The evaluation of the expression levels of metallopro-
teinases (MMP-2 and MMP-11); was based on the 
intensity and character of the staining of slides, recog-
nizing diffuse or granular forms. Identified were four 
levels of intensity of expression: 0 – negative, ie no 
observable reaction to the presence of metalloprotein-
ases, 1 – weak, ie when 20% of cells examined showed 
expression for metalloproteinases, 2 – medium, where 
20–50% of cells showed expression of metalloprotein-
ases (in this case also marked the grainy nature of the 
staining) and 3 – strong, where over 50% of the cells 
examined showed expression of metalloproteinases 
(Talvensaari-Mattila et al. 1999). Different degrees of 
expression of the enzymes are present photographs in 
Figures 1 and 2.
In immunohistochemical assays performed, metal-
loproteinase 2 (MMP-2) in 61 (56.5%) cases showed 
no expression of MMP-2, in 23 (21.3%) cases MMP-2 
expression was weak, in 11 (10.2%) average, and in 13 
(12.0%) cases, strong expression 
In the immunohistochemical assays performed, 
metalloproteinase 11 in 32 (29.62%) cases showed no 
expression of MMP-11, in 34 (31.5%) MMP-11 expres-
sion was weak, in 16 (14.8%) cases average expression 
and 26 (24%) cases of strong expression 
In the group of 99 women who survived the 10-year 
observation period were 61 (61.6%) cases where no 
expression of MMP-2 was confirmed, in 21 (21.2%) 
cases weak expression, in 9 (9.1%) cases average, and in 
8 (8.1%) cases, strong expression of MMP-2.
In the group of women whose observation ended 
with the death no cases with lack of expression of 
MMP-2 were observed; in 2 (22.2%) expression of 
MMP-2 was weak, in 2 (22.2%) average and 4 (55.6 %) 
cases of strong expression.
In the comparison of survival curves, Kaplan-
Meir for patients with different levels of expression of 
MMP-2, indicates the presence of statistically signifi-
cant differences in (p=0.05) survival time after surgery. 
The survival curve of patients in whom the level of 
expression of MMP-2 = 3 deviates significantly from 
the survival curves of patients with MMP-2 = 0, MMP-2 
= 1 and MMP-2 = 2. The 10-year survival of patients in 
the group with a strong expression of MMP-2 is signifi-
cantly lower than the 10-year survival of patients with 
absence, poor or average level of expression of MMP-2 
(Figure 3). 
In the group of 99 women who survived the 10-year 
observation period, 31 (31.3%) cases showed no 
expression of MMP-11, in the next 31 (31.2%) cases 
weak expression, in 14 (14.1%) cases average, and in 23 
(23.2%) cases, strong expression of MMP-11.
Fig. 1. Immunohistochemical reaction of the tested 
metalloproteinases. Lack of expression (0). 
Fig. 2. Immunohistochemical reaction of the tested metallo-
proteinases. Strong expression (3 +), intense granular reaction.
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The group, which resulted in fatal outcome, observation included: in 
1 (11.1) case showed no expression of MMP-11, in 3 (33.3%) expression 
of MMP-11 was weak, in 2 (22.2%) average expression, and in 3 (33.3%) 
cases strong expression.
There was no significant statistical difference in the level of MMP-11 
expression between the groups in which the therapeutic procedure was 
effective compared to that in which death were observed. Statistically 
10-year survival factor (p=0.487) was not significantly dependent on the 
level of expression of MMP-11, although in cases of women who sur-
vived the 10-year observation period no expression or low expression of 
MMP-11 was almost about 50% higher compared to the group where the 
tumor relapsed or patient died (Figure 4).
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Fig. 3. 10-year probability of survival, depending on the level of expression of MMP-2.
Fig. 4. 10-year probability of survival, depending on the level of expression of MMP-11.
Despite the lack of statistical sig-
nificance in the group where treat-
ment was completed successfully, 
dominating is the lack of expression 
of MMP-11.
DISCUSSION
Breast cancer is the most common 
malignancy in women. In developed 
countries, changing lifestyles, having 
fewer offspring, late first pregnancy, 
high-energy diet and long-term 
exposure to estrogen makes the 
incidence of this disease continue to 
grow.
Breast cancer is a disease of diver-
sity, and often inspite of similar 
clinical stage and histological differ-
entiation of tumor, patients are bur-
dened with different risk of relapse 
rate (Cianfrocca & Goldstein 2004). 
Still are sought some new, additional 
prognostic factors. Including these 
prognostic factors in the qualifica-
tion for further treatment could 
help in the emergence of a high-risk 
group of patients who benefit from 
additional treatment.
Intensively examined prognostic 
factors are associated with tumor 
cell biology. Cancer cells, including 
breast cancer cells, use proteolysis 
in the local processes of expansion 
and development of distant metas-
tases (Weigel & Dowsett 2010). 
They produce proteolytic enzymes, 
including metalloproteinases, as well 
as stimulating the fibroblasts, digest-
ing components of the extracellular 
matrix (ECM); among others, pro-
teoglycans and glycosaminoglycans, 
thereby gain the space needed for 
tumor growth. Furthermore, the 
tumor cells digesting collagen type 
IV, the main component of basement 
membranes, overcome this natural 
barrier, gaining the opportunity to 
invade the blood and lymph ves-
sels, and thus, the creation of distant 
metastases (Chandru et al. 2007; Kim 
2006; Mendes 2007; Talvensaari-
Mattila et al. 1999; Trangas et al. 
2001). Destruction of extracellular 
matrix components also reduces the 
strength of intercellular adhesion, 
facilitating detachment of cells from 
the tumor mass, which also facilitates 
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the process of metastasis. Metalloproteinases and pro-
angiogenic factors also indirectly participate in the next 
stage of expansion which is the process of tumor neo-
angiogenesis (Settner et al. 2009).
Physiologically, the activity of MMPs is strictly con-
trolled, while in the process of neoplastic changes its 
control is disordered, resulting in an increased expres-
sion of proteolytic enzymes (Trudel et al. 2003; Orn-
stein & Cohn 2002). Thus, increased expression of 
metalloproteinases is associated with increased tumor 
invasiveness (Benaud et al. 1998; Decock 2007; Nelson 
et al. 2000; Remackle et al. 1998).
The best known enzyme of this group is MMP-2. The 
prognostic value of this metalloproteinase in cancer is 
confirmed by many authors. Most work relates to its 
prognostic significance in solid tumors such as stomach 
cancer, prostate, bladder, small cell lung, ovarian and 
endometrial cancer (Micke & Őstman 2004; Perigny 
et al. 2008; pories et al. 2008; Talvensaari-Mattila et al. 
2005; Trudel et al. 2003). Cai et al. (2007), observed 
increased expression of MMP-2 and MMP-9 in the 
early stages of ovarian cancer and was closely associ-
ated with damage to the basement membrane. In stud-
ies, Trudel et al. (2003) also confirmed the prognostic 
value of MMP-2 in prostate cancer. In Talvensaari-
Mattila et al. studies the value of MMP-2 as a prognos-
tic factor in breast cancer patients with the presence of 
steroid receptors in tumor tissues has been confirmed. 
Its increased expression was associated with a shorter 
relapse-free period and with a shorter survival (Nako-
poulou et al. 2005; Talvensaari-Mattila et al. 1998; 1999; 
2001; 2003).
The objective of the study was to analyze the level 
of MMP-2 in the serum of patients with breast cancer 
too. Leppa (2004) confirmed the association of elevated 
serum levels with worse prognosis in the group of 
patients with metastases to axillary lymph nodes. The 
relationship of MMP-2 expression to breast cancer was 
also confirmed by Moses and colleagues (1998), and 
Pories et al. (2008), observing elevated levels in the 
urine of patients with breast cancer (Moses 1998).
In the analyzed material in the group of women 
who survived the 10-year observation period, in 61%, 
MMP-2 expression was negative, in 82% negative or 
weak, and in only 18% of cases, average or strong. How-
ever, in cases where the observation resulted in fatal 
outcome, in 77.7%, the expression of MMP-2 was aver-
age or strong, and in only 22.2%, weak. In this group 
there were no cases with lack of expression of MMP-2. 
In the Hirvonen studies (Hirvonen et al. 2003), the ratio 
of 10-year survival in patients without the presence of 
metastases to regional lymph nodes occurred 100% in 
the group with the lack of expression of MMP-2, and 
87% in the group with positive expression of MMP-2. 
After extracting the group with a strong expression 
of MMP-2, it was lower by another 3%.
The results of treatment are better than obtained in 
our material; however, as mentioned, the study group 
consisted only of patients with locally advanced disease, 
so with no lymph node involvement. The studies Tal-
vensaari showed 5-year survival of women with similar 
severity of disease, were 100% for the lack of expression 
of MMP-2 and 73% in the presence of MMP-2 (Talven-
saari-Mattila et al. 2003)
Of the more than 20 metalloproteinases usually ana-
lyzed as potential prognostic factors in breast cancer are 
MMP-2, MMP 9 and MMP 11. Expression of MMP-2 is 
often analyzed together with the expression of MMP-9, 
which is its direct activator (Braun et al. 2005). Due 
to the very different results for the MMP-9 as a prog-
nostic factor in breast cancer-even in the literature are 
reports of its importance as a positive prognostic factor 
in patients without metastasis to axillary lymph nodes 
(Pellikanen et al. 2002) – as the second test it was decided 
to choose metalloproteinase MMP-11, an enzyme from 
a completely different group of protease-dependent 
zinc ion, which are the stromelysins. MMP 11 is dif-
ferent from other metalloproteinases. In contrast to the 
other, it is secreted from cells after its activation in the 
Golgi apparatus. Therefore it requires no other cofac-
tors for its enzymatic activation. Its increased expres-
sion is observed in breast cancer, but also in pancreatic 
cancer (Łukaszewicz et al. 2008), stomach (Hua et al. 
2005), esophagus (Sharma et al. 2004) and small cell 
lung cancer (Janecki-Delebecq et al. 2000). In a study 
by Sharma et al (2004), increased MMP-11 expression 
in esophageal cancer was associated with worse out-
comes. What is also interesting, there was a correla-
tion between increased expression of MMP-11 and p53 
protein, which might suggest its role in regulating the 
expression of MMP-11. In studies by Janecki-Delebecq 
et al, elevated levels of MMP-11 expression was associ-
ated with the occurrence and metastasis of non-small 
cell cancer to local lymph nodes.
Most work is devoted to studying the role of 
MMP-11 in breast cancer; in the assessment of the 
prognostic value of metalloproteinases, in this type of 
cancer test results are more ambiguous than in the case 
of MMP-2. Initially it was thought that MMP-11 occurs 
only in tumor stromal cells, especially in fibroblasts 
(Pierzchała et al. 2004). But in their work, Tetu Ahmad 
confirmed their expression also in the cytoplasm of 
tumor cells. Described in the literature is the relation-
ship of increased expression of MMP-11 with worse 
prognosis in cancer. (Ahmad et al. 1998; Chenard et al. 
1996; Eiseler et al. 2009; Hanby et al. 1998; Nakopoulou 
ey al. 2002; Pei & Weis 1995; Pellikainem et al. 2002; 
Sato et al. 1997). It is known that in the figures of ductal 
carcinoma in situ – comedo type, which involves a high 
risk of developing invasive forms MMP-11 elevated 
expression was observed.
Many authors have not observed relation of MMP-11 
expression with survival and relapse-free time in breast 
cancer (Carter et al. 2003; Pacheco et al. 1998; Rudoph- 
Owen & Matrisian 1998). In the analysis of our material 
is also not a statistically significant relationship between 
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increased expression of MMP-11 and shorter survival. 
It should be noted that in the group of women who have 
survived a 10-year observation period, the percentage 
of cases with no or weak expression of MMP-11 was 
62.6%.
Perhaps the role of this enzyme is to initiate tumor 
growth through paracrine effects on the cells surround-
ing the tumor. Perhaps the evaluation of prognostic sig-
nificance of MMP-11 requires observation of a larger 
group of women with breast cancer.
It should be noted that the predictive value of 
Stromelysin 3 (MMP-11) in breast cancer was recently 
used in clinical practice. It enters into the composition 
of Oncotype DX diagnostic test (Paik et al. 2004; Van’t 
Veer et al. 2002). This is a panel of 21 genes for proteins 
with prognostic significance in breast cancer, whose 
genes are determined by RT-PCR (real time PCR). The 
value of the test has been confirmed in clinical studies 
on thousands of patients with breast cancer in N0 stage, 
characterized by the presence of steroid receptors. This 
test is helpful in extracting the group requiring treat-
ment beyond the use of additional chemotherapy and 
hormonal therapy. The St. Gallen expert panel in 2009 
recommended its use, but still with caution in terms of 
recognized prognostic factors.
CONCLUSION
Between two of the tested metalloproteinases (MMP-2 
and MMP-11) only MMP-2 appears to have prognos-
tic significance in early forms of breast cancer, and its 
strong expression is associated with shorter survival.
SUMMARY
Breast cancer is the most common malignancy in 
women in the U.S. and Europe. The ratio of cases of this 
cancer is constantly increasing. In the early stages of the 
disease, women are treated surgically, which is supple-
mented with hormonal therapy, immuno-, chemo-or 
radiotherapy. Postoperative qualification for further 
treatment is based on clinical stage, the pathology of the 
tumor and classic prognostic factors. 
Despite that, among patients with breast cancer in 
early stages of clinical advancement, there is a relatively 
large proportion of observed tumor recurrence. These 
observations oblige the search for additional prognos-
tic factors that determine the progression of the disease 
faster, according to which, could emerge a group of 
women at increased risk of recurrence of the disease. 
The immediate cause of death from breast cancer is 
metastasis of cancer cells to distant organs. The process 
of their formation is associated with the action of pro-
teolytic enzymes, including matrix metalloproteinases 
(MMPs).
Metalloproteinases are a group of zinc-dependent 
ion proteases involved in the proteolysis of extracel-
lular matrix components (ECM), including adhesive 
proteins and collagen. Their role has been confirmed in 
physiological processes such as embryogenesis, repair 
and reconstruction processes of tissue, angiogenesis, 
mammary gland involution and cyclic changes in endo-
metrial and pathological diseases such as cardiovascu-
lar diseases, chronic inflammatory diseases and cancer. 
They participate in the process of migration and metas-
tasis formation of cancer cells.
The aim of this study was to determine the mean-
ing of the expression of selected MMPs as prognostic 
factors in breast cancer. To achieve this goal, expres-
sion levels of MMP-2 and MMP-11 in the breast cancer 
tumors and the correlation between those expression 
and 10-years survival were determined. Our material 
consisted of 108 patients from ages 26 to 86 years treated 
surgically because of early primary breast cancer, ie in 
stage I and IIA according to the TNM classification in 
1994–2000 
In 101 cases, modified radical mastectomy and in 7 
cases breast conserving therapy with axillary lymph-
adenectomy was performed After the operation, the 
level of expression of selected MMPs, ie MMP-2 and 
MMP-11, was established. The effect of expression of 
selected MMPs on the results of treatment by means 
of the Kaplan-Maier curves were analyzed with the 
logrank test. The statistically significant level of signifi-
cance was adopted to be less than or equal to 0.05. The 
analysis showed no statistically significant dependence 
of the results of treatment; the level of expression of 
MMP-11 demonstrated a statistically significant cor-
relation between the ratio of 10-year experience, and 
the level of expression of MMP-2 (p=0.05). Based on 
the results of research and clinical observations, we 
concluded, that of the two metalloproteinases (MMP-2 
and MMP-11) only MMP-2 appears to have prognos-
tic value in early forms of breast cancer, and its strong 
expression is associated with shorter survival. 
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